Purmorphamine

Catalog No.S3042 Batch:S304203

Print

Technical Data

Formula

C31H32N6O2
Molecular Weight 520.62 CAS No. 483367-10-8
Solubility (25°C)* In vitro DMSO 50 mg/mL (96.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
2%DMSO 30%PEG300 5%Tween80 63%ddH2O
1.0mg/ml Taking the 1 mL working solution as an example, add 20 μL of clarified DMSO stock solution of 50 mg/ml to 300 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 630 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Purmorphamine (Shh Signaling Antagonist VI), which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM. Purmorphamine can reduce both basal and induced autophagy.
Targets
Smoothened [1]
(HEK293T cells)
~1.5 μM
In vitro

Purmorphamine activates the Hedgehog pathway by directly binds and activates Smoothened with IC50 of ~ 1.5 μM in compete with cyclopamine, a Smo antagonist. [1]

Purmorphamine is a potent inducer of osteogenesis in multipotent C3H10T1/2 cells. The EC50 (based on ALP expression) for Purmorphamine is 1 μM in C3H10T1/2 cells. Purmorphamine (1 μM) and BMP-4 (100 ng/mL) together increase ALP activity more than 90-fold in 3T3-L1 cells. [2]

In contrast to BMP-4, Purmorphamine induces osteogenesis by activating Hedgehog signaling in multipotent mesenchymal progenitor cells. [3]
In vivo

Purmorphamine up-regulates ALP expression in human mesenchymal stem cell-based constructs on rats. [4]

Protocol (from reference)

Kinase Assay:

[1]
  • Binding assay

    Smo binding assays are conducted with BODIPY-cyclopamine and Smo-overexpressing cells as previously described4,5, using CMV promoter-based, SV40 origin-containing expression constructs for Smo-Myc3, the deletion mutant SmoCRD (deletion of amino acids 68 to 182), and SmoCT (deletion of amino acids 556 to 793). HEK 293T cells are grown on poly-D-lysine-treated glass coverslips in 12-well plates until 70% confluency and then transfected with the appropriate expression construct (0.5 g/well) using FuGene 6 according the manufacturer
Cell Assay:

[2]
  • Cell lines

    C3H10T1/2 cell

  • Concentrations

    0.5-10 μM

  • Incubation Time

    4 days

  • Method

    C3H10T1/2 cells are expanded in T175 flasks; cells at 13th passage are detached by trypsin/EDTA and diluted in the growth media. The resulting cell suspension is then plated into black clear bottom 384-well plates with 2500 cells/well in 100 µL growth medium using a Multi-dropTM liquid delivery system. After overnight incubation, cells attached to the bottom of the wells. A stock solution of each Purmorphamine in DMSO (500 nL) is delivered into corresponding well using a Mini TrakTM multiposition dispenser system to make a final concentration of 5μM of Purmorphamine. Cells are then incubated at 37 ℃ with 5% CO2 in air atmosphere. After 4 days, the medium is removed and 10 μL of passive lysis buffer is added into each well. After 5 min, 10 μL of alkaline phosphatase substrate solution is added to each well. After incubating 15 min at room temperature, the plates are read on an Acquest high-throughput plate reader following the manufacturer's protocol.
Animal Study:

[5]
  • Animal Models

    Male C57BL/6J mouse pups

  • Dosages

    10 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , J Exp Clin Cancer Res, 2017, 36(1):23]

Data from [Data independently produced by , , Sci Rep, 2017, 7(1):1899]

Data from [Data independently produced by , , Phytother Res, 2017, 31(4):680-688]

Data from [Data independently produced by , , IUBMB Life, 2018, 70(2):143-152]

Selleck's Purmorphamine has been cited by 56 publications

Phosphorylation of human glioma-associated oncogene 1 on Ser937 regulates Sonic Hedgehog signaling in medulloblastoma [ Nat Commun, 2024, 15(1):987] PubMed: 38307877
Sonic hedgehog restrains the ubiquitin-dependent degradation of SP1 to inhibit neuronal/glial senescence associated phenotypes in chemotherapy-induced peripheral neuropathy via the TRIM25-CXCL13 axis [ J Adv Res, 2024, S2090-1232(24)00106-1] PubMed: 38479571
The MORC2 p.S87L mutation reduces proliferation of pluripotent stem cells derived from a patient with the spinal muscular atrophy-like phenotype by inhibiting proliferation-related signaling pathways [ Neural Regen Res, 2024, 19(1):205-211] PubMed: 37488868
Multiple factors to assist human-derived induced pluripotent stem cells to efficiently differentiate into midbrain dopaminergic neurons [ Neural Regen Res, 2024, 19(4):908-914] PubMed: 37843228
Host-to-graft propagation of inoculated α-synuclein into transplanted human induced pluripotent stem cell-derived midbrain dopaminergic neurons [ Regen Ther, 2024, 25:229-237] PubMed: 38283940
Human osteoarthritic chondrocytes up-regulate the expression of osteoprotegerin in osteoblasts via the Indian hedgehog signaling pathway [ Chinese Journal of Tissue Engineering Research, 2024, Vol. 28 ›› Issue (26): 4194-4201.] PubMed: none
Transplantation of neural stem progenitor cells from different sources for severe spinal cord injury repair in rat [ Bioact Mater, 2023, 23:300-313] PubMed: 36439085
Selective induction of human renal interstitial progenitor-like cell lineages from iPSCs reveals development of mesangial and EPO-producing cells [ Cell Rep, 2023, S2211-1247(23)01614-5] PubMed: 38237600
Small Molecule Cocktails Promote Fibroblast-to-Leydig-like Cell Conversion for Hypogonadism Therapy [ Pharmaceutics, 2023, 10.3390/pharmaceutics15102456] PubMed: 37896216
An engineered Sox17 induces somatic to neural stem cell fate transitions independently from pluripotency reprogramming [ Sci Adv, 2023, 9(34):eadh2501] PubMed: 37611093

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.